Diabetes and Metabolic Diseases Clinical Trial Landscape
Diabetes and metabolic diseases continue to drive significant global clinical research investment, fuelled by rising prevalence, increasing comorbidity burden, and demand for innovative therapies. Southern Star Research (SSR) supports sponsors across the full development lifecycle, delivering Phase I–III metabolic and diabetes clinical trials with a focus on operational precision, regulatory quality, and efficient execution.
Our experience spans diabetic foot ulcer, diabetic kidney disease, diabetic peripheral neuropathic pain, obesity, and Type 1 and Type 2 diabetes mellitus. We support programs from early-phase safety and pharmacokinetic studies through to later-phase efficacy and real-world evidence generation.
SSR combines Australia’s highly regulated clinical research environment with access to treatment-naïve patient populations across Asia, enabling sponsors to balance recruitment efficiency with globally recognised data quality. Our harmonised APAC delivery model supports faster recruitment, improved patient diversity, and consistent operational oversight across regions.
Our metabolic programs are supported by experienced endocrinology and diabetes specialists, including Dr. Jo Marjason, former Head of Endocrinology at Royal Brisbane & Women’s Hospital and an experienced Principal Investigator with expertise in metabolic disease and diabetes research.
SSR is also currently initiating a diabetic foot ulcer program targeting 120 patients across a regional hospital network, demonstrating our ability to execute complex studies beyond metropolitan site clusters while maintaining protocol integrity and recruitment continuity.
Australia continues to emerge as a high-performance hub for early-phase metabolic development due to rapid CTN start-up timelines, experienced investigator networks, globally accepted data standards, and cost efficiencies supported by the R&D Tax Incentive scheme.
Download our report to explore the latest trends, scientific developments, and investment activity shaping the future of longevity therapeutics.